# Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

> **NCT06161116** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 149 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** MK-6194
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06161116
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-27
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 149 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161116, "Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06161116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*